SRP 299

Drug Profile

SRP 299

Alternative Names: SR299; SRP299

Latest Information Update: 16 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SR Pharma
  • Developer Genesis Research and Development
  • Class Adjuvants; Antiallergics; Antiasthmatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic asthma; Atopic dermatitis

Most Recent Events

  • 31 Dec 2004 Discontinued - Phase-II for Atopic dermatitis in Ireland (Intradermal)
  • 31 Dec 2004 Discontinued - Phase-II for Atopic dermatitis in United Kingdom (Intradermal)
  • 04 Jun 2004 SRP 299 or AVAC will be available for licensing on the completion of current phase II trials (http://www.genesis.co.nz)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top